Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Pili

Showing results (111-120 of 223) with videos related to

Pageof 23
Sort By:
Free Radical Biology & Medicine|December 18, 2017
Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancerEric Ciamporcero, Martina Daga, Stefania Pizzimenti, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH|February 17, 2022
Autism and Visual impairment: A First Approach to a Complex RelationshipRoberto Pili, Bachisio Zolo, Pericle Farris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPCRoberto Pili, Mark A Rosenthal, Paul N Mainwaring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinomaYukihiko Kato, Kiyoshi Yoshimura, Tahiro Shin, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 26, 2004
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinomaUsha Sunkara, Janet R Walczak, Lori Summerson, et al.
Bioconjugate Chemistry|November 18, 2004
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifierKuo-Shyan Lin, Andrew Luu, Kwamena E Baidoo, et al.
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer modelHenk M W Verheul, Hans Hammers, Karen van Erp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumabJudith E Karp, Ivana Gojo, Roberto Pili, et al.
Molecular & Cellular Proteomics : MCP|March 30, 2023
Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade DifferentiationMarco Hadisurya, Zheng-Chi Lee, Zhuojun Luo, et al.
Pageof 23

Showing results (111-120 of 223) with videos related to

Sort By:
Pageof 23
Free Radical Biology & Medicine|December 18, 2017
Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancerEric Ciamporcero, Martina Daga, Stefania Pizzimenti, et al.
Clinical Practice and Epidemiology in Mental Health : CP & EMH|February 17, 2022
Autism and Visual impairment: A First Approach to a Complex RelationshipRoberto Pili, Bachisio Zolo, Pericle Farris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPCRoberto Pili, Mark A Rosenthal, Paul N Mainwaring, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinomaYukihiko Kato, Kiyoshi Yoshimura, Tahiro Shin, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 26, 2004
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinomaUsha Sunkara, Janet R Walczak, Lori Summerson, et al.
Bioconjugate Chemistry|November 18, 2004
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifierKuo-Shyan Lin, Andrew Luu, Kwamena E Baidoo, et al.
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer modelHenk M W Verheul, Hans Hammers, Karen van Erp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumabJudith E Karp, Ivana Gojo, Roberto Pili, et al.
Molecular & Cellular Proteomics : MCP|March 30, 2023
Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade DifferentiationMarco Hadisurya, Zheng-Chi Lee, Zhuojun Luo, et al.
Pageof 23